Literature DB >> 23377447

Ocular and cervical vestibular evoked myogenic potentials in patients with multiple sclerosis.

Tereza Gabelić1, Magdalena Krbot, Ana B Šefer, Velimir Išgum, Ivan Adamec, Mario Habek.   

Abstract

OBJECTIVES: The aim of this study was to evaluate latencies and corrected p13-n23 cervical vestibular evoked myogenic potentials (cVEMP) and n10-p13 ocular vestibular evoked myogenic potentials (oVEMP) amplitudes in patients with relapsing remitting multiple sclerosis (MS).
METHODS: This was a prospective, case-control study. Thirty patients with MS and 15 healthy controls were included. Cervical vestibular evoked myogenic potentials and oVEMP in response to acoustic clicks of 1 ms duration at the intensity of 130 dB SPL and the stimulation frequency of 1 Hz were studied. Signals were divided in segments of 120 ms duration (20 ms before the stimulus and 100 ms after the stimulus) and averaged.
RESULTS: In MS group, there was significant latencies prolongation of all sternocleidomastoid responses (p13 and n23) and n10 response of the ocular muscles. The sternocleidomastoid p13-n23 normalized amplitude was significantly higher in MS patients. Prolonged latencies were found in 57% and conduction block in 7% of patients in at least one sternocleidomastoid response in the MS group. Prolonged latencies were found in 30% and conduction block in 40% of patients in at least one ocular response in the MS group. When cVEMP and oVEMP are combined, 80% had pathological finding. When correlating brainstem clinical, brainstem MRI, and cVEMP findings, there was no statistical significance (brainstem clinical vs. cVEMP P = 0.1; brainstem MRI vs. cVEMP P = 0.82). When correlating brainstem clinical, brainstem MRI and oVEMP findings, there was a statistical significant correlation between brainstem clinical versus oVEMP, P = 0.02, whereas there was no statistical significance between brainstem MRI versus oVEMP (P = 0.38).
CONCLUSIONS: Combination of cVEMP and oVEMP in MS patients allows better estimation of brainstem lesions.

Entities:  

Mesh:

Year:  2013        PMID: 23377447     DOI: 10.1097/WNP.0b013e31827eda0c

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  7 in total

1.  Efficacy of cervical and ocular vestibular-evoked myogenic potentials in evaluation of benign paroxysmal positional vertigo of posterior semicircular canal.

Authors:  Niraj Kumar Singh; Kumari Apeksha
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-30       Impact factor: 2.503

Review 2.  Clinical utility of ocular vestibular-evoked myogenic potentials (oVEMPs).

Authors:  Konrad P Weber; Sally M Rosengren
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 3.  Vestibular-evoked myogenic potentials in central vestibular disorders.

Authors:  Sun-Young Oh; Hyo-Jeong Kim; Ji-Soo Kim
Journal:  J Neurol       Date:  2015-08-05       Impact factor: 4.849

4.  Vestibular evoked myogenic potentials in Bell's palsy.

Authors:  Magdalena Krbot Skoric; Ivan Adamec; Mario Habek
Journal:  Neurol Sci       Date:  2014-06-11       Impact factor: 3.307

5.  Effect of personal music system use on sacculocollic reflex assessed by cervical vestibular-evoked myogenic potential: A preliminary investigation.

Authors:  Niraj Kumar Singh; Chithra Sobha Sasidharan
Journal:  Noise Health       Date:  2016 Mar-Apr       Impact factor: 0.867

6.  Effects of multiple sclerosis on the audio-vestibular system: a systematic review.

Authors:  Evrim Gür; Ghada Binkhamis; Karolina Kluk
Journal:  BMJ Open       Date:  2022-08-17       Impact factor: 3.006

7.  Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12 month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo.

Authors:  J Marsden; M Pavlou; R Dennett; A Gibbon; R Knight-Lozano; L Jeu; C Flavell; J Freeman; D E Bamiou; C Harris; A Hawton; E Goodwin; B Jones; S Creanor
Journal:  BMC Neurol       Date:  2020-11-27       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.